LogicBio Therapeutics
Kendall Square
Cambridge
Massachusetts
United States
Tel: 781-771-5579
Website: http://www.logicbio.com/
Email: contact@logicbio.com
About LogicBio Therapeutics
A preclinical-stage company with a mission to develop cures for life-threatening diseases, LogicBio combines the best of gene therapy and genome-editing technology. Founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Children’s Medical Research Institute in Sydney – the company’s core platform includes its proprietary GeneRide technology and synthetic gene-therapy vectors derived from naturally occurring human adeno-associated viruses. LogicBio designed its approach to harness the natural power of homologous recombination - enabling precise, site-specific transfer of the genetic material without the use of promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases - focusing first on inborn errors of metabolism, where there are few, if any, treatment options. A number of the company’s discoveries have been featured in leading science publications and conferences. A private company, LogicBio is based in Cambridge, Massachusetts, with a research group in Tel Aviv.YEAR FOUNDED:
August 2015
LEADERSHIP:
Founders: Adi Barzel Ph.D., Mark Kay M.D. Ph.D. and Leszek Lisowski Ph.D.
President & CEO: Frederic Chereau
73 articles with LogicBio Therapeutics
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
11/15/2021
LogicBio Therapeutics, Inc., a clinical-stage genetic medicine company, reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate milestones.
-
LogicBio Therapeutics to Participate in Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
LogicBio Therapeutics, Inc., a clinical-stage genetic medicine company, announced that president and chief executive officer, Frederic Chereau, will participate at the following upcoming investor conferences.
-
LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using GeneRide™ Genome Editing Technology
10/21/2021
LogicBio Therapeutics, Inc. today is slated to present new preclinical data on its GeneRide™ platform at the European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, taking place October 19-22, 2021.
-
The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis.
-
On Monday, LogicBio Therapeutics unveiled clinical trial results demonstrating the first-ever in vivo, nuclease-free genome editing in little humans.
-
LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
10/18/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever in vivo genome editing in children.
-
LogicBio Therapeutics to Present New GeneRide™ Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
10/12/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), today announced that it was selected to present new data from the company's GeneRide™ platform in a plenary oral presentation and three poster presentations at the upcoming European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021.,
-
LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
9/24/2021
LogicBio Therapeutics, Inc. today announced that president and chief executive officer, Fred Chereau , will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 8:00 a.m. ET.
-
LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/10/2021
LogicBio Therapeutics, Inc. today announced that president and chief executive officer Fred Chereau will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.
-
LogicBio Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones
8/9/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate milestones.
-
LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021
7/8/2021
LogicBio Therapeutics, Inc. today announced that Frederic Chereau , chief executive officer of LogicBio, will participate in a virtual panel discussion entitled "Delivery and Durability of Genetic Medicines" at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET.
-
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia
6/2/2021
Company remains on track to announce update on enrollment, dose escalation and age de-escalation in late 2021 and interim data by year-end 2021
-
LogicBio Therapeutics to Participate in Upcoming Investor Conferences
6/1/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in virtual fireside chats at the following upcoming investor conferences
-
BioSpace Movers & Shakers, May 21
5/21/2021
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. -
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments
5/19/2021
- Stephen Boyer joined company as vice president, regulatory and quality affairs and Peter Pechan joined as vice president, gene therapy
-
BioSpace Movers & Shakers, May 14
5/14/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers. -
LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update
5/10/2021
- First patient for Phase 1/2 SUNRISE trial expected to be enrolled by mid-year 2021 - Business Development Deals signed with Daichi-Sankyo and CANbridge Pharmaceuticals - New members recently added to Leadership Team
-
LogicBio Therapeutics Strengthens Management Team with Key Appointments
5/10/2021
New leadership includes Andrea Paul as general counsel and corporate secretary, and Janice Olson as senior vice president, strategy and portfolio management, bringing extensive experience in gene therapy and rare disease
-
LogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
5/4/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced several preclinical data presentations, including an oral presentation, will be delivered at the 24th Annual American Society of Gene and Cell Therapy (ASGCT) Virtual Meeting